7 research outputs found
DISCORDANCE IN LEFT VENTRICULAR MASS INDEX BY CARDIAC MAGNETIC RESONANCE VERSUS ECHOCARDIOGRAPHY INCREASES IN HEART FAILURE
Death in Heart Failure: a Community Perspective
Abstract Background-Mortality in heart failure (HF) remains high but causes of death are incompletely defined. As HF is heterogeneous syndrome categorized according to ejection fraction (EF), the association between EF and causes of death is important, yet elusive
DISCORDANCE IN LEFT ATRIAL VOLUME MEASUREMENTS BY TRANSTHORACIC ECHOCARDIOGRAPHY VERSUS CMRI IN PATIENTS WITH AND WITHOUT HEART FAILURE
Asymptomatic Left Ventricular Systolic Dysfunction in Patients With Severe Aortic Stenosis
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management
Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences. Anthracyclines, chemotherapeutic drugs commonly used to treat children with cancer, are known to be cardiotoxic, but the mechanism by which they induce cardiac damage is still not fully understood. A higher cumulative anthracycline dose and a younger age of diagnosis are only a few of the many risk factors that identify the children at increased risk of developing cardiotoxicity. While cardiotoxicity can develop at anytime, starting from treatment initiation and well into adulthood, identifying the best cardioprotective measures to minimize the long-term damage caused by anthracyclines in children is imperative. Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children. Given the serious long-term health consequences of cancer treatments on survivors of childhood cancers, it is essential to investigate new approaches to improving the safety of cancer treatments